Mersacidin is a lanthionine-containing peptide antibiotic that shows a good in vivo efficiency against methicillin-resistant Stu~~ylococcus aureus. It is excreted during early stationary phase and could be purified from culture supematant in a one-step procedure by reversed phase HPLC. Its structural gene was cloned from chromosomal DNA of the producer strain Bacillus sub&is HIL Y-85,54728. Sequencing revealed that pre-mersacidin consists of an unusually long 48 amino acid leader sequence and a 20 amino acid propeptide part which is modified during biosynthesis to the mature Iantibiotic. The comparison of the mersacidin prepeptide with those of hitherto known lantibiotics demonstrates that mersacidin is more closely related to type B lantibiotic cinnamycin than to type A lantibiotics.
Introduction
Mersacidin belongs to a group of bactericidal peptides that was designated lantibiotics in order to signify that these peptides contain the rare amino acids lanthionine and/or 3-methyllanthionine [l] . Additional modified amino acids such as dehydroalanine and dehydrobutyrine occur regularly, while Saminovinylcysteine and lysinoalanine are found in some lantibiotics only [2] . Lantibiotics derive from ribosomally synthesized prepeptides and the lantibiotic structural genes have been found either on the bacterial chromosome (e.g. subtilin [3] and cinnamycin [4] ), or are associated with movable ele-ments such as transposons (e.g. nisin [5] ) or large plasmids (e.g. epidermin [l] ). The prepeptides consist of a C-terminal propeptide part which is modified and an N-terminal leader sequence which is cleaved off after the modification has been completed [2] . During the modification procedure, the serine and threonine residues are dehydrated to give dehydroalanine (Dha) or dehydrobutyrine (Dhb) [6] , which then react with the thiol-groups of the cysteine residues to form the lanthionines or methyllanthionines, respectively.
Mersacidin was isolated from the culture supernatant of Bacillus spec. HIL Y-85,54728 and gained interest because of its significant in vivo efficiency against methicillin-resistant Staphylococcus aweus (MRSA) [7] . It is the smallest lantibiotic isolated so far (1825 Da), synthesized from a propeptide of 20 amino acids and contains 3 methyllanthionine residues, one dehydroalanine and one S-aminovinyl- 2-methylcysteine ( Fig. 2A) [8]. Mersacidin carries no net charge and has overall hydrophobic properties. Recent results indicate that mersacidin interferes with the peptidoglycan biosynthesis [9] . This led us to clone and sequence the mersacidin structural gene as a basis for structure-function studies and peptide optimization by site-directed mutagenesis and to establish appropriate and rapid culture and purification methods.
Materials and methods

Production and purification
Bacillus spec. HIL Y-85,54728 was kept in tryptone soy broth with 50% of glycerol as a feed stock at -70" C. 200 ml of synthetic medium (50 mM glucose, 25 mM (NH,),SO,, 1 mM MgSO,, 0.5 mM CaCl,, 0.1 mM FeSO,, 0.05 mM MnSO,, 20 mM potassium phosphate buffer, 50 mM TRISmaleate buffer, pH 7 containing 10 ml per 1 of Wolfe's mineral salts [lo]) in 2 1 flasks were directly inoculated with 0.9 ml of feed stock and incubated at 30" C with agitation. The glucose concentration was determined according to Herbert et al. [ll] . The optical density was measured at 600 nm. For quantitation of mersacidin, supernatant was applied to a reversed phase (RP) column (Pores 10 R 2,4.6 X 100 mm, Perseptive Biosystems, Freiburg, Germany) using the following gradient (eluent A: 0.1% trifluoroacetic acid in water, eluent B: 0.1% trifluoroacetic acid in acetonitrile): 0 min: 5% B, 12 min 30% B, 16 min 33% B, 18 min 100% B, at a flow of 3 ml per min. The fractions were tested against Micrococcus luteus ATCC 4698 as indicator strain.
Cloning and sequencing of the structural gene of mersacidin
The depicted probe was synthesized as a 51-base guessmer on a PCR-Mate (Applied Biosystems, Weiterstadt, Germany) and labeled with digoxigenin (Boehringer, Mannheim, Germany) (Fig. 2B ). Chromosomal DNA was prepared as described by Marmur [12] . After one chloroform extraction and precipitation the DNA was dissolved in equilibration buffer and purified on a Qiagen-tip 100 column (Diagen, Hilden, Germany). At 52" C a single 2.1 kb band of a chromosomal restriction digest with Hind111 hybridized with the probe in a Southern blot in 5 X SSC. The fragments ranging from 1.9 to 2.3 kb in size were cut out from the gel, eluted with a BIOTRAP (Schleicher and Schiill, Dassel, Germany) and subcloned in pUC18 in E. coli 71-18 [13] . The plasmids of several recombinant colonies were prepared by the Bimboim and Doly method [13] , digested with Hind111 and probed with the guessmer. One of the clones that gave a positive signal was further analyzed by restriction digests with various enzymes and subsequent Southern blots. Finally, a 0.6 kb EcoR V fragment was cloned in the vector pCU1 [14] . Both strands of the 0.6 kb fragment were sequenced independently on an A.L.F. automatic DNA sequencer (Pharmacia, Brussels, Belgium) using the AutoRead sequencing kit (Pharmacia, Brussels, Belgium) from double stranded DNA, for priming the universal and reversal primer and two synthetic oligonucleotides S-(TCTC'ITCCATTITT-TTG)J and 5'-(AAATCAAATTAACAAATAC)3' were employed.
Results and discussion
Production and purification of mersacidin
In previous experiments, mersacidin production started after 45 h of cultivation [8] . We selected culture conditions as to minimize production time and to simplify purification of mersacidin. Fig. 1A shows a shake-flask experiment in a synthetic medium with glucose and ammonium. Like the lantibiotic subtilin, which is produced by Bacillus subtilis ATCC 6633 during early stationary phase [3], mersacidin production started at the onset of early stationary phase after 14 h. Repeated microscopic examinations gave no evidence of sporulation which was probably prevented by the excess glucose that was present at the end of exponential phase. Therefore, as with subtilin 131, the production of mersacidin seemed not to depend on sporulation or the presence of complex media components. The culture supematant was injected onto an RP HPLC column and mersacidin could be easily separated from the other constituents as shown in Fig. 1B . In conclusion, this culture system should be well adapted for rapid isolation and assessment of antibacterial activity of mutated mersacidin peptides.
Cloning and sequencing of the structural gene of mersacidin
The putative mersacidin propeptide sequence (Fig.  2B) was deduced from the structure of mersacidin and based on general information about lantibiotic biosynthesis. The aminobutyryl residues (Abus-half of methyllanthionine) derive from threonines while the alanine residues (Alas-half of methyllanthionine) are coded as cysteine in the propeptide. The Saminovinyl-2-methylcysteine, that forms the terminal ring structure is probably formed from threonine and a cysteine that has been oxidatively decarboxylated as shown for epidermin which contains a C-terminal S-aminovinylcysteine [15] . As plasmids could not be detected in the producer strain, chromosomal DNA was isolated and a 2.1 kb Hind III fragment that hybridized with the probe in a Southern blot was cloned. The nucleotide sequence of the mersacidin structural gene, mrsA, is shown in Fig. 3 . A potential ribosome binding site (AGG GGG) was found eight base pairs upstream of the ATG start codon of the open reading frame. The C-terminal part of the sequence is in agreement with the published mersacidin primary structure [8] and its proposed propeptide sequence. The N-terminal part consists of a 48 amino acid leader sequence. Therefore, the full length of the prepeptide is 68 amino acids with a calculated molecular mass of 7228 Da. Eight bases downstream of the TAA (ochre) stop codon a hairpin structure with a free energy value of -85,7 kJ mol-' and a stem size of 14 base pairs was found, which could serve as a rho-independent terminator during transcription as it is followed by a TTTATT sequence (Fig. 3) .
Comparison of the mersacidin prepeptide to type a and b lantibiotic prepeptides
Iantibiotics have been subdivided into two groups 121. Type A lantibiotics are elongated amphiphilic peptides that form transient pores in the membranes of sensitive bacteria [16] . Type B lantibiotics are globular peptides that are produced by Streptomyces, have molecular masses smaller than 2100 Da and are highly homologous as to their amino acid sequence and ring structure which includes a head to tail condensation [2] . Up to now mersacidin could not be classed with either group [17] . In this respect, the comparison of the prepeptide sequence of mersacidin with that of type A and B lantibiotics is of special interest. Two common characteristics of lantibiotic leader sequences have been preserved in mersacidin: i) There is no cysteine in the leader sequence [2] . ii) An a-helix propensity is predicted for the C-terminal part of the leader sequence. In every other respect the mersacidin leader sequence differs from the type A-lantibiotic leader sequences described so far: As shown in Fig. 4 it rather resembles in length and charge distribution (48 amino acids / 12 charges) the unusually long 59 amino acid leader ( of the type B lantibiotic cinnamycin [4] . In contrast, a typical highly charged type A lantibiotic leader sequence, e.g. the Pep5 leader peptide, contains 10 charged residues in a total of only 26 amino acids [18] . Conserved sequences of type A lantibiotics (e.g. the F D/N L D/E motif) are not found in the mersacidin leader peptide. The protease cleavage site of the mersacidin leader sequence ce4M --3E --"A---'A-+ 'C) differs more from the conserved sites of the type A lantibiotics (Fig. 41 , than from the cm4E --'A --2F --'A -+'C) cleavage site of cinnamycin [4] . In conclusion, the mersacidin prepeptide shows no homologies to the conserved sequences of type A-lantibiotic leader sequences. There is similarity to the prepeptide of cinnamycin in length and charge distribution, but no striking sequence homology on the amino acid level except a NPA and EAQ sequence which can be found in both peptides.
Mersacidin is smaller than type A-lantibiotics, it is not positively charged and it does not depolarize membranes, but rather inhibits peptidoglycan biosynthesis [9] . This, in addition to the properties of the leader peptide indicates that mersacidin is more related to type B than to type A lantibiotics. Recently, the sequence and bridging pattern of another lantibiotic, actagardine, which also inhibits cell wall biosynthesis [19] , have been revised. The third ring in mersacidin and the second ring in actagardine are almost completely conserved in both lantibiotics [20] . In view of the strong homology of the hitherto characterized type B lantibiotics duramycin A, B, C, ancovenin and cinnamycin, these peptides could also be regarded as structural variants as it is observed for epidermin and gallidermin [2, 20] . Therefore, we propose that mersacidin and actagardine should be classed with the type B lantibiotics and that the designation type B lantibiotic should not be exclusively reserved for structural variants of duramycin but comprise small, globular lantibiotics that carry a low charge and inhibit enzyme activity.
